Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : $16.0 million
Deal Type : Financing
4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing
Details : The financing is intended to support the company's lead product, 4P-004 (liraglutide), which is currently undergoing evaluation in early-stage clinical trials with patients for Knee Osteoarthritis.
Brand Name : 4P-004
Molecule Type : Peptide
Upfront Cash : Undisclosed
April 29, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : $16.0 million
Deal Type : Financing
Lead Product(s) : Plerixafor
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to to demonstrate the potential efficacy of Mozobil (plerixafor) in blocking CXCR4 receptor for the treatment of acute and long-lasting complications of COVID-19 in a Phase 2 global clinical trial.
Brand Name : Mozobil
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 23, 2021
Lead Product(s) : Plerixafor
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
